MX2015008400A - Concentrado previo de lipidos de liberacion prolongada de sustancia farmacologicamente activa cationica y composicion farmaceutica que comprende el mismo. - Google Patents
Concentrado previo de lipidos de liberacion prolongada de sustancia farmacologicamente activa cationica y composicion farmaceutica que comprende el mismo.Info
- Publication number
- MX2015008400A MX2015008400A MX2015008400A MX2015008400A MX2015008400A MX 2015008400 A MX2015008400 A MX 2015008400A MX 2015008400 A MX2015008400 A MX 2015008400A MX 2015008400 A MX2015008400 A MX 2015008400A MX 2015008400 A MX2015008400 A MX 2015008400A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained
- concentrate
- active substance
- pharmacologically active
- release
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 5
- 239000012730 sustained-release form Substances 0.000 title abstract 5
- 239000012141 concentrate Substances 0.000 title abstract 4
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 title abstract 3
- 125000002091 cationic group Chemical group 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000004973 liquid crystal related substance Substances 0.000 abstract 3
- 238000004873 anchoring Methods 0.000 abstract 2
- 125000000129 anionic group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 239000004848 polyfunctional curative Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe un concentrado previo de lípidos de liberación prolongada, que comprende: a) al menos un formador de cristal líquido; b) al menos un fosfolípido neutro; c) al menos un endurecedor de cristal líquido; y d) al menos un agente de anclaje aniónico, en donde el concentrado previo de liberación prolongada existe como una fase líquida de lípidos en ausencia de fluido acuoso y se forma en un cristal líquido en la exposición al fluido acuoso. El concentrado previo de lípidos de liberación prolongada se configura para mejorar la liberación prolongada de la sustancia farmacológicamente activa catiónica a través de la interacción iónica entre el agente de anclaje aniónico y la sustancia farmacológicamente activa catiónica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120157562A KR101586789B1 (ko) | 2012-12-28 | 2012-12-28 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
PCT/KR2013/012259 WO2014104784A1 (en) | 2012-12-28 | 2013-12-27 | Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008400A true MX2015008400A (es) | 2016-02-16 |
Family
ID=51021731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008400A MX2015008400A (es) | 2012-12-28 | 2013-12-27 | Concentrado previo de lipidos de liberacion prolongada de sustancia farmacologicamente activa cationica y composicion farmaceutica que comprende el mismo. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150265535A1 (es) |
EP (1) | EP2938331A4 (es) |
JP (1) | JP6246834B2 (es) |
KR (1) | KR101586789B1 (es) |
CN (1) | CN105050587A (es) |
AU (1) | AU2013371094B2 (es) |
BR (1) | BR112015015707A2 (es) |
CA (1) | CA2888711C (es) |
MX (1) | MX2015008400A (es) |
NZ (1) | NZ710472A (es) |
PH (1) | PH12015501183A1 (es) |
RU (1) | RU2649810C2 (es) |
WO (1) | WO2014104784A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120288537A1 (en) * | 2010-01-13 | 2012-11-15 | The Regents Of The University Of Michigan | Active self-healing biomaterial system |
KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
PL2877155T3 (pl) | 2012-07-26 | 2021-05-17 | Camurus Ab | Formulacje opioidowe |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
KR101586791B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
DK2943474T3 (en) | 2013-01-31 | 2017-08-21 | Chong Kun Dang Pharmaceutical Corp | BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXE DERIVATE COMPOUNDS AS CETP INHIBITORS |
KR101601035B1 (ko) | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
KR101809908B1 (ko) * | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | 5-알파환원효소억제제를 포함하는 조성물 |
BR112016029338A2 (pt) | 2014-07-29 | 2017-08-22 | Therapeuticsmd Inc | creme transdérmico |
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
GB201516554D0 (en) * | 2015-09-18 | 2015-11-04 | Camurus Ab | Controlled-release formulations |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
BR112019006904A2 (pt) * | 2016-10-04 | 2019-07-02 | Cellix Bio Private Ltd | composições e métodos para tratamento de xerostomia |
WO2019014201A1 (en) * | 2017-07-10 | 2019-01-17 | Apicore Us Llc | MOLINDONE COMPOSITIONS WITH EXTENDED RELEASE |
WO2019045355A1 (ko) * | 2017-08-29 | 2019-03-07 | 대원제약 주식회사 | 리바스티그민 파모산염의 제조방법 |
AU2018338924B2 (en) * | 2017-09-27 | 2020-05-21 | Novel Pharma Inc. | Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same |
KR102197257B1 (ko) * | 2017-10-19 | 2020-12-31 | 단국대학교 천안캠퍼스 산학협력단 | 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물 |
IL274233B2 (en) * | 2017-11-17 | 2024-04-01 | Cellix Bio Private Ltd | Compounds, preparations and methods for the treatment of eye disorders and skin diseases |
EP3651747A4 (en) * | 2017-11-17 | 2020-07-22 | Cellix Bio Private Limited | COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISORDERS |
BR112020015436A2 (pt) * | 2018-02-05 | 2020-12-22 | Cellix Bio Private Limited | Composição farmacêutica, mistura física e uso de uma composição |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
MX2021004027A (es) * | 2018-10-15 | 2021-08-11 | Chong Kun Dang Pharmaceutical Corp | Composiciones de microparticulas inyectables de naltrexona de accion prolongada. |
WO2020109957A1 (en) * | 2018-11-26 | 2020-06-04 | Cellix Bio Private Limited | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases |
WO2020144546A1 (en) * | 2019-01-12 | 2020-07-16 | Cellix Bio Private Limited | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
KR102365844B1 (ko) * | 2019-02-18 | 2022-02-22 | (주)아이엠디팜 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
KR102186704B1 (ko) * | 2019-02-18 | 2020-12-04 | (주)아이엠디팜 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
CA3102364A1 (en) * | 2019-03-26 | 2020-10-01 | Novel Pharma Inc. | Long-acting fatty acid-conjugated gnrh derivatives and pharmaceutical compositions containing same |
KR102096391B1 (ko) * | 2019-10-11 | 2020-04-06 | (주)아이엠디팜 | 액상결정 구조체를 형성하는 오메가-3-지방산 조성물 |
US20240050448A1 (en) * | 2020-12-30 | 2024-02-15 | Biocorrx, Inc. | Biodegradable Implant Including Naltrexone and Cholesterol |
WO2023080712A1 (ko) * | 2021-11-05 | 2023-05-11 | ㈜아이엠디팜 | 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물 |
WO2023249465A1 (ko) * | 2022-06-23 | 2023-12-28 | 주식회사 지투지바이오 | 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0669268B2 (ja) | 1985-11-22 | 1994-08-31 | 松下電工株式会社 | 充電回路 |
GB9302492D0 (en) * | 1993-02-09 | 1993-03-24 | Procter & Gamble | Cosmetic compositions |
FR2709666B1 (fr) * | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
EP0760237A1 (en) * | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6919372B1 (en) * | 1997-12-26 | 2005-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Sustained release pharmaceutical compositions |
TWI241915B (en) | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
WO2006075124A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
PL1682091T3 (pl) * | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
GB0409066D0 (en) * | 2004-04-23 | 2004-05-26 | Ici Plc | Surfactant composition |
SG173326A1 (en) * | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
US9060935B2 (en) * | 2005-01-21 | 2015-06-23 | Camurus Ab | Pharmaceutical lipid compositions |
DE602007010941D1 (de) * | 2006-07-13 | 2011-01-13 | Bang & Olufsen As | Kombinierter elektrochemischer und laser-mikrobearbeitungsprozess zur erzeugung von ultradünnen flächen |
US20080102128A1 (en) * | 2006-07-28 | 2008-05-01 | Flamel Technologies, Inc. | Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them |
US9918934B2 (en) * | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
CA2714514C (en) * | 2008-02-08 | 2016-08-16 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
CA2743551C (en) * | 2008-11-19 | 2017-08-15 | Merial Limited | Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol |
CA2828086C (en) * | 2010-03-10 | 2018-07-31 | Nuvo Research Inc. | Foamable formulation |
CN101978947B (zh) * | 2010-10-20 | 2012-04-18 | 南京日升昌生物技术有限公司 | 一种长效硫酸头孢喹诺注射液及其制备方法 |
KR101319420B1 (ko) * | 2011-03-18 | 2013-10-17 | 한남대학교 산학협력단 | 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템 |
KR101494594B1 (ko) * | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
KR101586791B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | GnRH 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
-
2012
- 2012-12-28 KR KR1020120157562A patent/KR101586789B1/ko not_active IP Right Cessation
-
2013
- 2013-12-27 CN CN201380068015.5A patent/CN105050587A/zh active Pending
- 2013-12-27 US US14/440,058 patent/US20150265535A1/en not_active Abandoned
- 2013-12-27 CA CA2888711A patent/CA2888711C/en not_active Expired - Fee Related
- 2013-12-27 RU RU2015131112A patent/RU2649810C2/ru not_active IP Right Cessation
- 2013-12-27 WO PCT/KR2013/012259 patent/WO2014104784A1/en active Application Filing
- 2013-12-27 MX MX2015008400A patent/MX2015008400A/es unknown
- 2013-12-27 AU AU2013371094A patent/AU2013371094B2/en not_active Ceased
- 2013-12-27 EP EP13866593.0A patent/EP2938331A4/en not_active Withdrawn
- 2013-12-27 JP JP2015550321A patent/JP6246834B2/ja not_active Expired - Fee Related
- 2013-12-27 BR BR112015015707A patent/BR112015015707A2/pt not_active IP Right Cessation
- 2013-12-27 NZ NZ710472A patent/NZ710472A/en not_active IP Right Cessation
-
2015
- 2015-05-27 PH PH12015501183A patent/PH12015501183A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014104784A4 (en) | 2014-07-31 |
RU2649810C2 (ru) | 2018-04-04 |
US20150265535A1 (en) | 2015-09-24 |
AU2013371094A1 (en) | 2015-08-13 |
EP2938331A1 (en) | 2015-11-04 |
RU2015131112A (ru) | 2017-02-01 |
CA2888711C (en) | 2018-01-02 |
AU2013371094B2 (en) | 2016-11-17 |
KR101586789B1 (ko) | 2016-01-19 |
JP2016508140A (ja) | 2016-03-17 |
EP2938331A4 (en) | 2016-08-10 |
NZ710472A (en) | 2016-04-29 |
JP6246834B2 (ja) | 2017-12-13 |
PH12015501183A1 (en) | 2015-08-17 |
WO2014104784A1 (en) | 2014-07-03 |
CN105050587A (zh) | 2015-11-11 |
KR20140086722A (ko) | 2014-07-08 |
CA2888711A1 (en) | 2014-07-03 |
BR112015015707A2 (pt) | 2017-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501183A1 (en) | Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same | |
PH12015501554A1 (en) | Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same | |
MX2016006896A (es) | Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica. | |
EP2750667A4 (en) | LIPID PRECONCENTRATE WITH DELAYED RELEASE FROM A PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION THEREWITH | |
MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
MX360391B (es) | Composiciones liposomales combinadas para terapia contra el cancer. | |
MX2018003096A (es) | Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. | |
FR3007969B1 (fr) | Distributeur d'une dose unitaire d'une substance active sous une forme galenique solide | |
EA201791738A1 (ru) | Пролипосомальные композиции тестостерона | |
MX2015008021A (es) | Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. | |
UY34899A (es) | Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos | |
TN2013000373A1 (en) | Pharmaceutical formulation comprising inositol | |
UA118562C2 (uk) | Модулятори рецептора cxcr7 | |
MX2015005762A (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
FR2984750B1 (fr) | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii | |
PH12016501117A1 (en) | Pharmaceutical compositions of carotenoid | |
MX359436B (es) | Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol. | |
MD20150054A2 (ro) | Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron | |
MX352361B (es) | Composicion para el cuidado oral conteniendo liquidos ionicos. | |
GB201204632D0 (en) | Delivery system | |
GB2501427A (en) | A washing capsule for providing washing compositions to a machine | |
NZ702849A (en) | Genotype- or phenotype-based drug formulation | |
IN2014DN07897A (es) | ||
IN2013MU03543A (es) | ||
MY175531A (en) | Sterically stabilized unsaturated fatty acid liposome |